{"name":"Shandong Suncadia Medicine Co., Ltd.","slug":"shandong-suncadia-medicine-co-ltd","ticker":"","exchange":"","domain":"shandongsuncadiamedicine.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"cardiovascular","drugs":[{"name":"Fluvustat","genericName":"Fluvustat","slug":"fluvustat","indication":"Other","status":"phase_1"},{"name":"HRS-1780 Tablets","genericName":"HRS-1780 Tablets","slug":"hrs-1780-tablets","indication":"Other","status":"phase_3"},{"name":"HRS-1893 Tablets","genericName":"HRS-1893 Tablets","slug":"hrs-1893-tablets","indication":"Other","status":"phase_3"},{"name":"HRS-7085","genericName":"HRS-7085","slug":"hrs-7085","indication":"Other","status":"phase_2"},{"name":"HRS-7535 Tablets","genericName":"HRS-7535 Tablets","slug":"hrs-7535-tablets","indication":"Other","status":"phase_3"},{"name":"HRS-7535 tablet","genericName":"HRS-7535 tablet","slug":"hrs-7535-tablet","indication":"Other","status":"phase_3"},{"name":"HRS-8080 Tablets","genericName":"HRS-8080 Tablets","slug":"hrs-8080-tablets","indication":"Other","status":"phase_3"},{"name":"Reference formulation of HRS-1893 tablet","genericName":"Reference formulation of HRS-1893 tablet","slug":"reference-formulation-of-hrs-1893-tablet","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Everolimus Tablets","genericName":"Everolimus Tablets","slug":"everolimus-tablets","indication":"Advanced renal cell carcinoma","status":"marketed"},{"name":"Fulvestrant injection ;Dalpiciclib Isethionate","genericName":"Fulvestrant injection ;Dalpiciclib Isethionate","slug":"fulvestrant-injection-dalpiciclib-isethionate","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"HRS-8080 Tablet ; Dalpiciclib Isethionate","genericName":"HRS-8080 Tablet ; Dalpiciclib Isethionate","slug":"hrs-8080-tablet-dalpiciclib-isethionate","indication":"Hormone receptor-positive, HER2-negative breast cancer (in combination with endocrine therapy)","status":"phase_3"},{"name":"Tamoxifen Citrate Tablets","genericName":"Tamoxifen Citrate Tablets","slug":"tamoxifen-citrate-tablets","indication":"Adjuvant treatment of breast cancer","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HRS-5346","genericName":"HRS-5346","slug":"hrs-5346","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"HRS-5346","genericName":"HRS-5346","slug":"hrs-5346","phase":"phase_2","mechanism":"HRS-5346 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Everolimus Tablets","genericName":"Everolimus Tablets","slug":"everolimus-tablets","phase":"marketed","mechanism":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.","indications":["Advanced renal cell carcinoma","Breast cancer (hormone receptor-positive, HER2-negative)","Pancreatic neuroendocrine tumors","Subependymal giant cell astrocytoma (SEGA)","Organ transplant rejection prevention"],"catalyst":""},{"name":"Fluvustat","genericName":"Fluvustat","slug":"fluvustat","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fulvestrant injection ;Dalpiciclib Isethionate","genericName":"Fulvestrant injection ;Dalpiciclib Isethionate","slug":"fulvestrant-injection-dalpiciclib-isethionate","phase":"phase_3","mechanism":"This combination uses fulvestrant to block estrogen receptors in breast cancer cells while dalpiciclib inhibits cyclin-dependent kinases 4 and 6 to prevent cell cycle progression.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"HRS-1780 Tablets","genericName":"HRS-1780 Tablets","slug":"hrs-1780-tablets","phase":"phase_3","mechanism":"HRS-1780 is an investigational small molecule with unknown mechanism of action in Phase 3 development.","indications":[],"catalyst":""},{"name":"HRS-1893 Tablets","genericName":"HRS-1893 Tablets","slug":"hrs-1893-tablets","phase":"phase_3","mechanism":"HRS-1893 is an investigational small molecule with unknown mechanism of action in Phase 3 development.","indications":[],"catalyst":""},{"name":"HRS-7085","genericName":"HRS-7085","slug":"hrs-7085","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-7535 Tablets","genericName":"HRS-7535 Tablets","slug":"hrs-7535-tablets","phase":"phase_3","mechanism":"HRS-7535 is an investigational small molecule with unknown mechanism of action in Phase 3 development.","indications":[],"catalyst":""},{"name":"HRS-7535 tablet","genericName":"HRS-7535 tablet","slug":"hrs-7535-tablet","phase":"phase_3","mechanism":"HRS-7535 tablet's mechanism of action is not publicly available.","indications":[],"catalyst":""},{"name":"HRS-8080 Tablet ; Dalpiciclib Isethionate","genericName":"HRS-8080 Tablet ; Dalpiciclib Isethionate","slug":"hrs-8080-tablet-dalpiciclib-isethionate","phase":"phase_3","mechanism":"Dalpiciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that blocks cell cycle progression by preventing phosphorylation of the retinoblastoma protein.","indications":["Hormone receptor-positive, HER2-negative breast cancer (in combination with endocrine therapy)"],"catalyst":""},{"name":"HRS-8080 Tablets","genericName":"HRS-8080 Tablets","slug":"hrs-8080-tablets","phase":"phase_3","mechanism":"HRS-8080 is an investigational small molecule with unknown mechanism of action in Phase 3 development.","indications":[],"catalyst":""},{"name":"Reference formulation of HRS-1893 tablet","genericName":"Reference formulation of HRS-1893 tablet","slug":"reference-formulation-of-hrs-1893-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tamoxifen Citrate Tablets","genericName":"Tamoxifen Citrate Tablets","slug":"tamoxifen-citrate-tablets","phase":"phase_3","mechanism":"Tamoxifen Citrate Tablets work by competitively inhibiting estrogen receptors on tumor cells.","indications":["Adjuvant treatment of breast cancer","Treatment of metastatic breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOU3N1M2NTQzZCMkg2SzR1N0JjUWo5NVRzQnc5bUwzMFZ3dTZDb09MUmJ6NFlDOTkzdkdodFRhVnFaR05RaVZScXpwMmMyb09jZGtIQmo0VUpGX0JCXzRXeGd5anB6OW56V1BqTXE1clk4UklTX21GVWZhQ2dWODF6a0JtT1ZVSjlsSFdPQ1praUVtSnNyaDJXQ3pEZFFKUF8yM0xGbTRYMA?oc=5","date":"2026-03-31","type":"trial","source":"BioWorld News","summary":"Braveheart finds phase II positive for cardiac myosin inhibitor - BioWorld News","headline":"Braveheart finds phase II positive for cardiac myosin inhibitor","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQck9rUVhUUmJZSE1PODVOdkNyTWI4enQ5MUFnWnNuTE9HM1MzbDVNSGVPWkVfckx4eS1wZjFrTHBOYi1MT0x2anNpOF83anl6Y2dlUXcxaWNGRm5vdjBUTjhKT29PMUZ2eEhIRXNNa3lsb3lreHJvZW1CS3NrelRXWmJqUEZWNU9lTjBFaFMxQXM0Nmk2MEo3RVVfWVVwOVVPcGlPaS1HM09jVkxH?oc=5","date":"2025-12-30","type":"pipeline","source":"Pharmacy Times","summary":"HRS-1780 Demonstrates Positive Safety, Efficacy Treating Patients With CKD - Pharmacy Times","headline":"HRS-1780 Demonstrates Positive Safety, Efficacy Treating Patients With CKD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNc1FiWWhJQVg1OVVxSXc0OVZOQjc5RmNvbklhYWZXdy04ZGFwWkRIcGZPdUV3RmhqRzdfUWV2dTBseVdkQVd6d1pNUlZ1X2FNRTg1N0REbU93U1dzRVZ5RVVhdkhrNE54aG4xZ1RJY0JlOVZabUpwbEJWU3dwdm9OYWJNbWI0T1V1eEhJcjd0WndOX0VQTHRqWE9MYlk1WlBkd0E?oc=5","date":"2025-09-05","type":"deal","source":"BioWorld News","summary":"Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal - BioWorld News","headline":"Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOQk8xcmM1b0pkdXBGS1kzTmZ3MUI2a0dVZDRBc0JMSlR1aEVXT3NfZGFSZ25PdlBvNmhsWEdrZjJkOHdua1lnZU5oaDNHM1lZNVN3NzBSRUpfem9CQU9KcmZtVzFJd2lTTS1TSjNjV0Y5UkdZQy1KRmZQRENvT2Z2NTVUY2FQQ2Jra0hyZ2VkVXBvM3M?oc=5","date":"2025-01-14","type":"pipeline","source":"BioWorld News","summary":"CSPC wins China clearance of new DPP-4 inhibitor - BioWorld News","headline":"CSPC wins China clearance of new DPP-4 inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNbDVNY2Vtekhac0k0RU5Rc0hGN3FTVFA2UTRaMlRvbnduYW54TEtEUFpmdjIzYWUxQ1k1Rmt4R3JtVEtPTkFQMWRhTmxtOEctdGJMN0RCSlJ2dWxsWWRkN0xucC1ETkxZSnhEX0JEeGZVTXpTMjZSeDJwbWphbGRQa3lNTEFkTG5XOUZDZ1ZSa0JXWFlUbGFhRDZ0M29QSlIxQUg1Rk8wMXlUUEFEWG5CQndyS0tDQVp2T2tmM0lzeTZRSEtIbk1DVzY3ZWVpX0RZcWJ6MWtSS0FJd21JTTNwVXcxeHpBSXJlVHl3MmIxMUtlQWVLaVlfTVhvWUdobkRiVDFTM0pkWTFYSHo4RjN3TU1VYUV5dk1XZjRya3ptcUwwREpUamVveE9QYU4zSUxSU3djOWZNTQ?oc=5","date":"2024-10-01","type":"trial","source":"GlobeNewswire","summary":"Breast Cancer Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Breast Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"phase_2":2,"marketed":1,"phase_1":2,"phase_3":8},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}